ストックスクリーナーアプリを入手
24.99
0.73%
0.18
前日終値:
$24.81
開ける：
$24.82
24時間の取引高:
1.02M
Relative Volume:
1.27
時価総額：
$2.81B
収益：
$454.68M
当期純損益:
$-178.68M
株価収益率:
-15.42
EPS:
-1.6209
ネットキャッシュフロー:
$-135.66M
1週間 パフォーマンス:
+2.71%
1か月 パフォーマンス:
-0.36%
6か月 パフォーマンス:
+20.49%
1年 パフォーマンス:
-23.58%
1日の値動き範囲:
$24.35
$25.92
1週間の範囲:
$23.76
$26.92
52週間の値動き範囲:
$15.96
$33.65
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Compare ZLAB vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
24.99 | 2.81B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-14 | 開始されました | Morgan Stanley | Overweight |
| 2023-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 開始されました | Macquarie | Outperform |
| 2021-10-12 | 開始されました | Bernstein | Mkt Perform |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-04-15 | 開始されました | Guggenheim | Buy |
| 2019-07-12 | 開始されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
| 2019-01-29 | 開始されました | Credit Suisse | Outperform |
| 2018-11-21 | 開始されました | Jefferies | Buy |
| 2018-06-21 | 再開されました | Leerink Partners | Outperform |
| 2018-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 開始されました | JP Morgan | Neutral |
| 2017-10-16 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Zai Lab Limited Adr (ZLAB) 最新ニュース
Zai Lab Limited (9688.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer - marketscreener.com
Zai Lab stock trades without a verified September catalyst - AD HOC NEWS
ZLAB - Finviz
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In T - Benzinga
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Zai Lab LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
ZLAB Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Slip 2.76%Earnings Surprise Stocks - dars.gov.et
ZLAB Stock Price, Quote & News - Syfe
Zai Lab LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Former Zai Lab (NASDAQ: ZLAB) executive lines up multi-million ADS sale - Stock Titan
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordEPS Miss Report - dars.gov.et
Zai (ZLAB) EPS and Revenue: The Available Earnings Metric Delivers a Beat in Latest Trading; Market Response: Shares Finish 2.08% Down in the Available RecordOne-Time Loss Impact - dars.gov.et
Zai Lab (NASDAQ: ZLAB) holder lines up Aug. 19 ADS sale after recent trades - Stock Titan
Zai Lab: Revenue Growth And Zoci's Upside Optionality (NASDAQ:ZLAB) - Seeking Alpha
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Yahoo Finance
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock - MarketBeat
William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case? - Sahm
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Zai Lab CFO Chen Yajing Sells 619 ADS Shares via Rule 10b5-1 Trading Plan - Kalkine Media
Zai Lab (NASDAQ:ZLAB) Shares Gap DownWhat's Next? - MarketBeat
Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ - Stock Titan
ZLAB (NASDAQ: ZLAB) filer plans sale of 619 American Depositary Shares - Stock Titan
Zai Lab (ZLAB) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Earnings Turnaround - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Guidance vs Actual - dars.gov.et
ZLAB Q2 2026 Earnings: Narrower Loss Beats Consensus by 24%Basic EPS Analysis - dars.gov.et
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen - Sahm
Zai Lab Q2 Earnings Call Highlights - finance.yahoo.com
Zai Lab Q2 Earnings Call Highlights - sharewise.com
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Form 8K ZAI LAB LIMITED For: 6 August By Investing.com - Investing.com Nigeria
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings - MarketBeat
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M - Stock Titan
Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M - Stock Titan
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - BioSpace
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab’s zoci targets previously treated neuroendocrine cancers - Stock Titan
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) - Business Wire
Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday - MarketBeat
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
Zai Lab Limited Adr (ZLAB) 財務データ
収益
当期純利益
現金流量
EPS
Zai Lab Limited Adr (ZLAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Smiley Joshua L | Former Officer |
Aug 20 '26 |
Proposed Sale |
26.18 |
98,653 |
2,582,511 |
0 |
| Chen Yajing | Officer |
Aug 19 '26 |
Proposed Sale |
27.00 |
260 |
7,020 |
0 |
| Lis William | Director |
Aug 12 '26 |
Proposed Sale |
25.00 |
8,506 |
212,650 |
0 |
| Lis William | Director |
Aug 12 '26 |
Sale |
25.00 |
8,506 |
212,650 |
41,931 |
| Chen Yajing | Chief Financial Officer |
Aug 11 '26 |
Sale |
25.00 |
619 |
15,475 |
35,072 |
| Chen Yajing | Officer |
Aug 11 '26 |
Proposed Sale |
25.00 |
619 |
15,475 |
0 |
| GAYNOR RICHARD | Director |
Jul 01 '26 |
Buy |
19.05 |
1,736 |
33,071 |
80,737 |
| Du Ying | Chairperson & CEO |
Jun 30 '26 |
Sale |
18.53 |
7,026 |
130,220 |
1,203,784 |
| Du Ying | Officer |
Jun 30 '26 |
Proposed Sale |
18.53 |
7,026 |
130,220 |
0 |
| Edmondson Frazor Titus III | Chief Legal Officer |
Jun 26 '26 |
Sale |
17.46 |
4,103 |
71,642 |
30,346 |
2.76%
0.02%
大文字化:
|
ボリューム (24 時間):